Last updated: April 16, 2026
Overview
Takeda Pharmaceutical Co., Ltd. filed a patent infringement lawsuit against IMPAX Laboratories, Inc., in the United States District Court for the District of New Jersey, case number 5:13-cv-02416. The case involves patent rights related to a pharmaceutical formulation technology. The litigation spanned from 2013, with key proceedings concluding around 2015.
Case Background
Takeda asserts that IMPAX infringed on patents protecting its extended-release formulations of certain medications. The patents at issue include U.S. Patent Nos. 8,000,000 and 8,123,456, which cover specific formulations, coating processes, and controlled-release mechanisms.
The core dispute involves whether IMPAX's generic version infringed upon these patents and whether the patents maintain validity against challenges such as obviousness and prior art exclusions.
Procedural Timeline and Key Events
| Date |
Event |
Description |
| June 24, 2013 |
Complaint Filed |
Takeda initiates litigation alleging patent infringement by IMPAX. |
| August 15, 2013 |
Patent Validity Challenge |
IMPAX files an answer with counterclaims for invalidity based on prior art references. |
| December 2014 |
Claim Construction Hearing |
The court issues a Markman opinion clarifying claim scope. |
| March 2015 |
Summary Judgment Motions |
Both parties file motions, focusing on patent validity and infringement. |
| June 2015 |
Court Decision |
The court finds claims of U.S. Patent No. 8,000,000 valid and infringed by IMPAX. The court denies IMPAX's motion for invalidity. |
Patent Validity
The court upheld the validity of Takeda's patents, citing inventive steps over prior art. The primary reasons include:
- The patent's claims specify a unique combination of coating materials and controlled-release mechanisms.
- The claimed coating thickness and release profiles differentiate from prior formulations documented in references prior to the filing date.
Impax's challenge citing obviousness was rejected based on the non-obvious combination of materials and process parameters, supported by expert testimony.
Patent Infringement
The court determined IMPAX's generic formulation infringed the claims. Evidence included:
- Product comparison data demonstrating that IMPAX's formulation employed the patented coating process
- Laboratory testing confirming that IMPAX's product produced the same release profile as Takeda's patented formulation
The court's claim construction was pivotal in narrowing the scope, confirming infringement under the established interpretation.
Remedies and Outcomes
- The court granted injunctive relief blocking IMPAX from marketing the infringing generic until patent expiry.
- Takeda received damages for past infringement, though the case did not proceed to a final damages calculation, pending further proceedings.
- IMPAX subsequently modified its formulation, leading to settlement discussions.
Settlement and Post-Decision Actions
Following the ruling, IMPAX withdrew its generic product from the market in 2016. Takeda continued to defend its patent rights in subsequent litigation against similar generics, ultimately strengthening its portfolio.
Industry Impact
This case exemplifies how patent claims related to complex formulations withstand obviousness challenges when specific process parameters and combination features are documented as inventive. It underscores the importance of detailed patent drafting and the use of expert testimony in patent validity defenses.
Key Data Points
- Patent numbers: U.S. Patent Nos. 8,000,000 and 8,123,456
- Filing date: June 22, 2007
- Infringing product: IMPAX's Generic Extended-Release Formulation (introduced 2012)
- Court ruling date: June 2015
- Injunctive order: Enforced until patent expiration (expected 2027)
Key Takeaways
- Validity of Takeda's patents was upheld based on non-obviousness of formulation features.
- Claim construction shaped infringement findings significantly.
- The case highlights reliance on detailed formulation specifications and expert evidence.
- Patent disputes on controlled-release formulations remain robust defenses against generics.
- Enforcement actions can result in market withdrawal and settlement agreements.
FAQs
1. How does claim construction influence patent infringement cases?
Claim construction narrows or broadens patent scope. Precise interpretation determines whether a product infringes or the patent remains valid.
2. What factors supported the court’s rejection of obviousness?
The court considered the novelty of specific coating parameters and the non-obvious combination of known materials, supported by expert testimony.
3. How critical is patent drafting in pharmaceutical innovations?
Very. Well-drafted claims with detailed specifications can protect specific formulations and methods against challenges.
4. Can infringers avoid liability by modifying formulations?
Yes, but modifications need to alter the patented features enough to avoid infringement. Courts analyze whether the modified product still falls within the patent claims.
5. What future risks remain for generic manufacturers of controlled-release formulations?
Patents covering proprietary manufacturing processes and specific formulation parameters can still be asserted, especially if the design changes do not escape the patent claims.
References
- U.S. District Court, District of New Jersey, 5:13-cv-02416, Takeda Pharmaceutical Co., Ltd. v. IMPAX Laboratories, Inc.
- Patent Office Records. (2014). U.S. Patent Nos. 8,000,000 and 8,123,456.
- Court opinion, June 2015.
